Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Orencia ClickJect, Orencia
Synonyms :
abatacept
Class :
DMARDs, Immunomodulators; Immunosuppressants
Brand Name :
Orencia ClickJect, Orencia
Synonyms :
abatacept
Class :
DMARDs, Immunomodulators; Immunosuppressants
Dosage forms & Strengths:
Adult:
Lyophilized Powder for Injection
250 mg/vial
Solution for Subcutaneous injection
125 mg/ml (prefilled syringe, autoinjector)
IV bolus
weight <60 kg: 500 mg
weight 60-100 kg: 750 mg
weight >100 kg: 1000 mg
Maintenance: Repeat the aforementioned dose every two weeks for two weeks, then every four weeks
Subcutaneous (SC)
You can start SC with or without an IV loading dose
Give the first SC injection if an IV loading dose is taken within a day following the infusion
125 mg SC every 7 days
Making the switch from IV to SC:
Instead of the planned IV dosage, administer the first SC dose
IV bolus
weight <60 kg: 500 mg
weight 60-100 kg: 750 mg
weight >100 kg: 1000 mg
Maintenance: Repeat the aforementioned dose every two weeks for two weeks, then every four weeks
Subcutaneous (SC)
You can start SC with or without an IV loading dose
Give the first SC injection if an IV loading dose is taken within a day following the infusion
125 mg SC every 7 days
Making the switch from IV to SC:
Instead of the planned IV dosage, administer the first SC dose
IV bolus
weight <60 kg: 500 mg
weight 60-100 kg: 750 mg
weight >100 kg: 1000 mg
Maintenance: Repeat the aforementioned dose every two weeks for two weeks, then every four weeks
Subcutaneous (SC)
You can start SC with or without an IV loading dose
Give the first SC injection if an IV loading dose is taken within a day following the infusion
125 mg SC every 7 days
Making the switch from IV to SC:
Instead of the planned IV dosage, administer the first SC dose
Lyophilized Powder for Injection
250 mg/vial
Solution for Subcutaneous injection
125 mg/ml (prefilled syringe)
Refer to the adult dosing
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may diminish the therapeutic effect of vaccines
poliovirus vaccine inactivated
may diminish the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may enhance the risk of adverse effects of abatacept
it may reduce the therapeutic effect of covid-19 vaccines 
Corticosteroids may diminish the therapeutic effect of Immune Checkpoint Inhibitors.
Corticosteroids may diminish the therapeutic effect of Immune Checkpoint Inhibitors.
Corticosteroids may diminish the therapeutic effect of Immune Checkpoint Inhibitors.
Corticosteroids may diminish the therapeutic effect of Immune Checkpoint Inhibitors.
Corticosteroids may diminish the therapeutic effect of Immune Checkpoint Inhibitors.
Immunosuppressants may reduce the therapeutic effect of COVID-19 Vaccine
it may enhance the immunosuppressive effect of Immunosuppressants
it may diminish the therapeutic effect of Influenza Virus Vaccines
influenza virus vaccine h n live
it may diminish the therapeutic effect of Influenza Virus Vaccines
influenza virus vaccine (h n ) adjuvanted
it may diminish the therapeutic effect of Influenza Virus Vaccines
it may diminish the therapeutic effect of Influenza Virus Vaccines
poliovirus vaccine, live, trivalent
immunosuppressants may diminish the therapeutic effect of Vaccines
poliovirus vaccine inactivated
immunosuppressants may diminish the therapeutic effect of Vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of corticosteroids
may decrease the therapeutic effect
may decrease the therapeutic effect of COVID-19 vaccine
may increase the risk or severity of toxic effects when combined
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may enhance the metabolism of each other when combined
abatacept increases the metabolism of vernakalant
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
vaccinia immune globulin intravenous (Rx)
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
poliovirus vaccine, live, trivalent
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
poliovirus vaccine inactivated
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
smallpox (vaccinia) vaccine, live
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
immunosuppressants may enhance the adverse/toxic effect of Vaccines
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
it may increase the immunosuppressive effect of abatacept 
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
smallpox (vaccinia) vaccine, live
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
may enhance the adverse/toxic effect of BCG products
may increase the immunosuppressive effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
vaccinia immune globulin intravenous (Rx)
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
poliovirus vaccine, live, trivalent
may increase the adverse/toxic effect of immunosuppressants
poliovirus vaccine inactivated
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
smallpox (vaccinia) vaccine, live
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
measles, mumps, rubella and varicella vaccine, liveÂ
may increase the toxic effects of varicella virus containing vaccine
it increases the toxicity of rubella or varicella-containing live vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)Â
may enhance the adverse/toxic effect of rubella, and varicella vaccine, live 
immunosuppressants increase the effect of baricitinib
immunosuppressants increase the toxicity of BCG products
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the effect of immunosuppression of natalizumab
it increases the effect of immunosuppressants
immunosuppressants increase the toxicity of the poliovirus vaccine
immunosuppressants increase the effect of immunosuppression of ruxolitinib
immunosuppressants increase the effect of immunosuppression of tacrolimus
immunosuppressants increase the toxicity of talimogene laherparepvec
immunosuppressants increase the effect of immunosuppression of tofacitinib
immunosuppressants increase the toxicity of the typhoid vaccine
immunosuppressants increase the effect of immunosuppression of upadacitinib
measles, mumps, rubella, and varicella vaccine, live (Rx)
immunosuppressants increase the toxicity of live vaccines
measles mumps and rubella vaccine, live
immunosuppressants increase the toxicity of live vaccines
immunosuppressants increase the toxicity of the yellow fever vaccine
may decrease the therapeutic effect of antibiotics
may increase the immunosuppressive effect
may increase the metabolism of Epinastine when combined
the toxicity of either of the drugs is increased by immunosuppressive activity
amoxicillin and clavulanate potassium
may diminish the therapeutic effect of immune checkpoint inhibitors
lansoprazole, amoxicillin, and clarithromycin
may diminish the therapeutic effect of immune checkpoint inhibitors
bismuth subcitrate, metronidazole and tetracycline
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
it may enhance the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with azelastine
When netupitant is used alongside abatacept, its metabolism may also be accelerated
it may enhance the risk of side effects when combined with mitomycin
ximelagatran (investigational)Â
The combination of abatacept may lead to an enhanced metabolism of ximelagatran
Combining methysergide and abatacept can enhance methysergide's metabolism
Combining levobetaxolol and abatacept can enhance levobetaxolol’s metabolism
It may enhance the risk of adverse effects when combined with antihyperlipidemic
It may enhance the risk of adverse effects when combined with antihyperlipidemic
It may enhance the risk of adverse effects when combined with antihyperlipidemic
It may enhance the risk of adverse effects when combined with antihyperlipidemic
It may enhance the risk of adverse effects when combined with antihyperlipidemic
When acetohexamide is used together with abatacept, this lead to rise in acetohexamide’s metabolism
When mometasone furoate is used together with abatacept, this leads to enhanced risk or seriousness of adverse outcomes
When encainide is used together with abatacept, this leads to a rise in the encainide’s metabolism
abatacept will increase the metabolism of terfenadine when used in combination
when coupled with abatacept, metronidazole's metabolism can be accelerated
combining mycophenolic acid with abatacept may heighten the risk or severity of adverse effects
abatacept: it may increase the metabolism of lornoxicam
abatacept: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may increase the metabolism of oxprenolol
abatacept: it may increase the metabolism of pipotiazine
the risk or extent of adverse effects can be increased when abatacept is combined with tepoxalin
combining abatacept with diethylstilbestrol can raise its metabolism
dengue vaccine efficacy will be reduced by abatacept by immunosuppression
when both drugs are combined, the risk or severity of adverse effects increases  
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may enhance the immunosuppressive effect of immunosuppressants
immunosuppressants may reduce the therapeutic effect of COVID-19 Vaccine
Immunosuppressants may enhance the immunosuppressive effect of Inebilizumab.
may enhance the immunosuppressive effect of baricitinib
immunosuppressants decrease the efficacy of brincidofovir
imipenem/cilastatin/relebactamÂ
may decrease the therapeutic effect of antibiotics
amoxicillin and clavulanate potassium
antibiotics may reduce the therapeutic effect of immune checkpoint inhibitors
lansoprazole, amoxicillin, and clarithromycin
antibiotics may reduce the therapeutic effect of immune checkpoint inhibitors
bismuth subcitrate, metronidazole and tetracycline
antibiotics may reduce the therapeutic effect of immune checkpoint inhibitors
antibiotics may reduce the therapeutic effect of immune checkpoint inhibitors
antibiotics may reduce the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune Checkpoint inhibitors
may diminish the therapeutic effect of immune Checkpoint inhibitors
may diminish the therapeutic effect of immune Checkpoint inhibitors
may diminish the therapeutic effect of immune Checkpoint inhibitors
may diminish the therapeutic effect of immune Checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may diminish the therapeutic effect
amoxicillin and clavulanate potassium
may diminish the therapeutic effect
bismuth subcitrate, metronidazole and tetracycline
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
neomycin/polymyxin B/gramicidin ophthalmicÂ
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of acetaminophen
acetaminophen and phenyltoloxamine
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
acetaminophen and phenyltoloxamine
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may decrease the therapeutic effect when combined
acetaminophen/doxylamine/dextromethorphanÂ
may decrease the therapeutic effect when combined.
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
ciprofloxacin inhaled (Pending FDA approval)Â
may diminish the therapeutic effect of antibiotics
it increases the effect of ototoxicity of aminoglycosides Immune Checkpoint Inhibitors
It may diminish the metabolism when combined with Fluroquinolones
It may diminish the metabolism when combined with Fluroquinolones
It may diminish the metabolism when combined with Fluroquinolones
It may diminish the metabolism when combined with Fluroquinolones
It may diminish the metabolism when combined with Fluroquinolones
fluindione metabolism is increased when used in combination with abatacept
the risk of adverse effects may be increased when abatacept is taken with fluocortolone
hepatitis A vaccine inactivatedÂ
when used with abatacept, the Hepatitis A Vaccine's therapeutic efficacy may be compromised
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
abatacept can increase the metabolism of dihydroergocristine when combined with it
the rate of metabolism of dihydroergocornine may be increased
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
meningococcal group B vaccineÂ
the efficacy of the vaccine may be reduced
the risk of adverse effects can be increased
the coadministration of abatacept with ivacaftor has the potential to enhance the metabolism of ivacaftor
the rate of metabolism of lifelong may be increased
the rate of metabolism of cethromyucin may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the rate of metabolism of candesartan cilexetil may be increased
antithymocyte globulin rabbitÂ
the risk or extent of adverse effects can be raised when anti-thymocyte immunoglobulin (rabbit) is combined with abatacept
the rate of metabolism of methoxyflurane may be increased
the risk or intensity of negative effects can be heightened when abatacept is combined with filgotinib
When abatacept is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
the danger or seriousness of adverse effects can be heightened when abatacept is combined with strepronin
may decrease the therapeutic effect of drug
may diminish the therapeutic effect of drug
neomycin/polymyxin B/bacitracin topical
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
immunosuppressants decrease the efficacy of the COVID-19 vaccine
it increases the effect of immunosuppressive agents
immunosuppressants decrease the efficacy of the influenza virus vaccine
immunosuppressants increase the effect of immunosuppression of leflunomide
immunosuppressants decrease the efficacy of the rabies vaccine
measles, mumps, rubella, and varicella vaccine, live (Rx)
immunosuppressants decrease the efficacy of vaccines
measles mumps and rubella vaccine, live
immunosuppressants decrease the efficacy of vaccines
Actions and Spectrum:
abatacept is a biologics medication used to treat autoimmune disorders such as rheumatoid arthritis. It works by inhibiting the activation of T cells, involved in the body’s immune response.
It leads to a reduction in the inflammation and joint damage that occurs in autoimmune disorders. abatacept is an immunomodulatory drug that modulates or regulates the immune system. It is administered by intravenous infusion.
>10%:
Headache (18%)
Nasopharyngitis (12%)
Nausea (>10%)
1-10%:
Dizziness (9%)
Cough (8%)
Hypertension (7%)
Back pain (7%)
Urinary Tract Infection (6%)
Dyspepsia (6%)
Pain in extremities (3%)
Rash (4%)
<1%:
Anaphylaxis
COPD exacerbation
Cellulitis
Disease flare
Dyspnea
Diverticulitis
Hypersensitivity
Joint wear
Lymphoma
Pruritus
Urticaria
Rhonchi
Wheezing
Varicella infection
Frequency Not Defined:
Nausea
Diarrhea
Abdominal pain
Black Box Warning:
It is essential to follow the dosage and administration instructions for the medication carefully.
Contraindication/Caution:
abatacept is contraindicated in individuals with hypersensitivity to abatacept or its components.
Cautions:
Pregnancy consideration:
Category C.
Breastfeeding warnings:
The presence of the drug in breast milk and its effect on lactating infants is unknown.
Pregnancy category:
Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
abatacept is a biologics medication that modulates the immune system to reduce inflammation in autoimmune disorders. It is a selective co-stimulation modulator that binds to CD80 and CD86, co-stimulatory molecules on antigen-presenting cells (APCs).
By binding to these co-stimulatory molecules, abatacept interferes with the interaction between APCs and T cells, involved in the body’s immune response. It reduces T cells’ activation, reducing inflammation and joint damage in autoimmune disorders such as rheumatoid arthritis.
Pharmacodynamics:
abatacept is a biologics medication that blocks the activation of T-cells, involved in the body’s immune response. It specifically targets the co-stimulatory signal needed for T-cell activation, thus reducing inflammation, and slowing down the progression of autoimmune diseases such as rheumatoid arthritis. abatacept modulates the immune system by binding to CD80 and CD86 on antigen-presenting cells, preventing the interaction with CD28 on T-cells. This results in a decreased activation of T-cells and decreased production of pro-inflammatory cytokines, leading to reduced inflammation and joint damage.
Pharmacokinetics:
After SC administration, abatacept is absorbed more slowly, with peak plasma concentrations occurring between 24-72 hours.
Following IV administration, abatacept is rapidly distributed into the bloodstream, with peak plasma concentrations occurring within 1-2 hours.
The drug is then slowly cleared from the body through metabolism and excretion.
Terminal Half-life: 13 days
Peak Plasma concentration: 295 mcg/mL
The volume of distribution: 0.07 L/kg
Rate of Clearance: 0.22 mL/hr/kg
Administration:
Administer the medication intravenously or subcutaneously. Dilute the powder with 10 ml of sterile water for injection to obtain 25 mg/ml of solution.
Patient information leaflet
Generic Name: abatacept
Pronounced: ab-a-tah-sept
Why do we use abatacept?
abatacept treats Rheumatoid Arthritis, Psoriatic Arthritis, Graft versus Host Disease, and Juvenile Idiopathic Arthritis in children.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
